2023
The Endocannabinoid System - The Prediction of Spontaneous Preterm Birth in High-Risk Women: Protocol of a Study
PARIZEK, Antonin, Martin HILL, Michaela DUSKOVA, Lucie KOLATOROVA, Josef SUCHOPAR et. al.Základní údaje
Originální název
The Endocannabinoid System - The Prediction of Spontaneous Preterm Birth in High-Risk Women: Protocol of a Study
Autoři
PARIZEK, Antonin (203 Česká republika), Martin HILL (203 Česká republika), Michaela DUSKOVA (203 Česká republika), Lucie KOLATOROVA (203 Česká republika), Josef SUCHOPAR (203 Česká republika), Patrik SIMJAK (203 Česká republika), Katerina ANDERLOVA (203 Česká republika), Eva KUDOVA (203 Česká republika), Vladimir ROGALEWICZ (203 Česká republika), Jaroslav VACEK (203 Česká republika), Marcela KOUDELKOVÁ (203 Česká republika, domácí), Renata CHLOUPKOVÁ (203 Česká republika, domácí), Miroslava ALBLOVA (203 Česká republika), Petra PARIZKOVA (203 Česká republika), Zdenek LASTUVKA (203 Česká republika) a Miroslav BARTAK (203 Česká republika, garant)
Vydání
Physiological research, Praha, Institute of Physiology of the Czechoslovak Academy of Sciences, 2023, 0862-8408
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30105 Physiology
Stát vydavatele
Česká republika
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 2.100 v roce 2022
Kód RIV
RIV/00216224:14110/23:00133344
Organizační jednotka
Lékařská fakulta
UT WoS
001127421100002
Klíčová slova anglicky
Anandamide (AEA); Endocannabinoids; Endocannabinoid system; 2-arachidonoylglycerol (2-AG); 2-linoleoylglycerol (2-LG); 2-oleoylglycerol (2-OG); 2-arachidonoyldopamine (2-ADOPA center dot NADA); Predicting preterm birth; Spontaneous preterm birth (sPTB)
Změněno: 21. 3. 2024 14:44, Mgr. Tereza Miškechová
Anotace
V originále
Spontaneous preterm birth (sPTB) is a major cause of perinatal morbidity and mortality, even in developed countries. Prediction of sPTB is therefore a valuable tool to reduce the associated risks. The current standard for the prediction of sPTB consists, in addition to anamnestic data, of previous sPTB and previous second trimester miscarriage, measurement of cervical length by transvaginal ultrasound (TVU CL) together with assessment of fetal fibronectin levels in cervicovaginal fluid. Other evaluation parameters, such as the level of endocannabinoids in the pregnant woman's blood, could increase the sensitivity of this management. Endocannabinoids (eCBs) are a part of the endocannabinoid system (ECS); out of them anandamide (arachidonoyl-ethanolamide, AEA), in particular, plays an important role in the regulation of pregnancy and childbirth. We present the protocol for an open, non-randomized study to evaluate concentrations of AEA and other endocannabinoids: 2-linoleoylglycerol (2-AG), 2-linoleoylglycerol (2-LG), 2-oleoylgly-cerol (2-OG), and 2-arachidonoyldopamine (2-ADOPA or also NADA) in the blood of pregnant women as potential predictors of sPTB. In a total of 230 women with a history of sPTB or miscarriage, eCBs levels between 22 and 28 weeks of gestation will be assessed from maternal blood, in addition to the standard procedure. The aim of the study is to determine the relationship between blood concentrations of the endocanna-binoids tested and the risk of sPTB. The results of this study will describe the prognostic significance of maternal blood eCBs levels for sPTB, and could subsequently enable improved screening programs for early identification of sPTB.